Creat Group will attempt to restructure its $1.5M offer to acquire Biotest after U.S. regulators nixed the deal.
November 11, 2017
Deals and Financings
- China’s Creat Group will attempt to restructure its $1.5 billion offer to acquire Biotest, a German blood plasma company, after US regulators nixed the deal;
- Valeant Pharma closed its $190 million sale of California-based Obagi Medical Products to a group that includes China Regenerative Medicine;
- Zhejiang Huahai Pharma acquired China rights to an immuno-oncology candidate discovered by Eutilex of South Korea in a $65 million agreement that included a $30 million investment in Eutilex;
- EOC Pharma Group of Shanghai, an oncology spin-out from China in-licensing company Eddingpharm, closed a $32 million B funding round;
- AnchorDx Corp of Guangzhou raised $28 million in a Series B round to develop precision oncology products using next-generation sequencing technology;
- Exicure, a Chicago developer of nucleic acid drugs, closed a $11.2 million funding led by Yantai-based Luye Pharma;
- Ark Biosciences of Shanghai partnered with the California Institute for Biomedical Research of La Jolla to develop novel therapies for COPD and other lung diseases;
Company News
- Sweden’s Genovis signed a China distribution agreement with Shanghai Titan Scientific for its portfolio of enzymes that are used in making biologic drugs;
- Cellular Biomedicine held an official opening for its new Shanghai CAR-T manufacturing facility, located in Zhangjiang High-Tech Park.
Stock Symbols: (DE: BIOG) (NYSE: VRX) (HK: 2186) (NSDQ: CBMG)
